Double-blind clinical study comparing alprazolam and doxepin in primary unipolar depression

Alprazolam; Double-blind clinical study; Doxepin; Primary unipolar depression; Depressive Disorder; Adolescent; Adult; Aged; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychological Tests; Clinical Trials as Topic

Abstract :

[en] The therapeutic effect and safety of alprazolam and doxepin were studied in 126 outpatients suffering from primary unipolar depression. The 6-week study was double-blind with a random allocation of treatment. Patients were treated with a flexible dose of 1.0-4.5 mg of alprazolam and 50-225 mg of doxepin per day. The mean final doses were 2.7 mg for alprazolam and 137.5 mg for doxepin. The results indicate that alprazolam and doxepin were equally efficacious. The incidence of side-effects was lower in the alprazolam treatment group. © 1984.

Disciplines :

Treatment & clinical psychology

Author, co-author :

ANSSEAU, Marc ; Université de Liège - ULg

Ansoms, C.; Psychiatrische Kliniek, B-3300 Tienen, Belgium

Beckers, G.; Psychiatric Clinic Medister, B-2070 Ekeren, Belgium, Belgium

Bogaerts, M.; Otterstraat, B-2300 Turnhout, Belgium

Botte, L.; Centre Hospitalier de Tivoli, B-7100 La Louvière, Belgium

De Buck, R.; Institut de Psychiatrie, Hôpital Universitaire Brugmann, B-1200 Brussels, Belgium

Diricq, S.; Unité de Psychopharmacologie, Hôpital Universitaire de Baviére, B-4020 Liège, Belgium

Dumortier, A.; Kliniek Heilige Familie, B-8500 Kortrijk, Belgium

Jansegers, E.; Venneborglaan 41, B-2100 Deurne, Belgium

Owieczka, J.; Avenue Léo Errera 54, B-1180 Brussels, Belgium

Stellamans, G.; Algemeen Ziekenhuis, Psychiatrische Afdeling, B-8000 Bruges, Belgium

Language :

English

Title :

Double-blind clinical study comparing alprazolam and doxepin in primary unipolar depression

Publication date :

1984

Journal title :

Journal of Affective Disorders

ISSN :

0165-0327

eISSN :

1573-2517

Publisher :

Elsevier, Netherlands

Volume :

Issue :

3-4

Pages :

287-296

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 07 May 2021

Statistics

Number of views

74 (3 by ULiège)

Number of downloads

365 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Rudzik, Hester, Tang, Straw, Friis (1973) Triazolobenzodiazepines, a new class of central nervous system-depressant compounds. The Benzodiazepines , S. Garattini, E. Mussini, L.O. Randall, Raven Press, New York; 285-297.
Fabre, McLendon (1979) A double-blind study comparing the efficacy and safety of alprazolam with diazepam and placebo in anxious outpatients. Curr. Ther. Res. 25:519-526.
McLendon, Fabre (1979) A double-blind comparison of the anxiolytic efficacy of alprazolam and chlordiazepoxide hydrochloride in the chronic withdrawal period from alcohol. Curr. Ther. Res. 26:430-439.
Aden, Thein (1980) Alprazolam compared to diazepam and placebo in the treatment of anxiety. J. Clin. Psychiat. 41:245-248.
Greiss, Fogari (1980) Double-blind clinical assessment of alprazolam, a new benzodiazepine derivative, in the treatment of moderate to severe anxiety. J. Clin. Pharmacol. 20:693-699.
Maletzky (1980) Anxiolytic efficacy of alprazolam compared to diazepam and placebo. J. Int. Med. Res. 8:139-143.
Botte, Bienfait, Dethier, Even, Evrard, Fraipont, Goffin, Willemse (1981) Comparaison clinique entre alprazolam et lorazepam — Une étude polycentrique en double insu. Acta Psychiat. Belg. 81:595-608.
Cohn (1981) Multicenter double-blind efficacy and safety study comparing alprazolam, diazepam and placebo in clinically anxious patients. J. Clin. Psychiat. 42:347-351.
Feighner, Aden, Fabre, Rickels, Smith (1983) Multiclinic double-blind safety and efficacy comparison of alprazolam, imipramine and placebo in the treatment of major depressive disorder. J. Amer. Med. Ass. 249:3057-3064.
Feighner (1983) Alprazolam, imipramine and placebo in the treatment of major depressive disorder — A double-blind study. Acta Psychiat. Scand. 68:223-233.
Feighner (1983) Open-label study of alprazolam in severely depressed inpatients. J. Clin. Psychiat. 44:332-334.
Pitts (1983) Open-label study of alprazolam in severely depressed inpatients. J. Clin. Psychiat. 44:213-215.
Sethy (1982) A possible mode of antidepressant activity of alprazolam. Benzodiazepine Symposium, Washington; .
Secunda (1980) Doxepin — Recent pharmacologic and clinical studies. The Physiology of Affective Disorders , J. Mendels, J.D. Amsterdam, Karger, Basel; 130-146.
Hollister, Overall, Pikorny, Shelton (1971) Acetophenazine and diazepam in anxious depressions. Arch. Gen. Psychiat. 24:273-279.
Freeman, Bourne, Schiff (1974) The treatment of anxious/depressive states — A double-blind comparison of medazepam with fluphenazine/nortriptyline. J. Int. Med. Res. 2:197-202.
Rickels, Raab, DeSilverio, Etemad (1967) Drug treatment in depression. JAMA 201:105-111.
Rickels, Hesbacher, Downing (1970) Differential drug effects in neurotic depression. Dis. Nerv. Syst. 31:468-475.
Rickels, Chung, Feldman, Gordon, Kelly, Weise (1973) Amitriptyline, diazepam and phenobarbital sodium in depressed outpatients. J. Nerv. Ment. Dis. 157:442-451.
Daneman (1970) A comparative trial of medazepam (Nobrium) in anxiety-depressive states. Psychosomatics 10:366-369.
Kellner (1973) Chlordiazepoxide in depressive neurosis — An open-label crossover study with amitriptyline. Can. Psychiat. Ass. J. 18:393-399.
Covi, Lipman, Derogatis (1973) Imipramine, diazepam and group psychotherapy in long-term treatment of depressive neurotics. Psychopharmacol. Bull. 9:57-59.
Shammas (1977) Controlled comparison of bromazepam, amitriptyline and placebo in anxiety-depressive neurosis. Dis. Nerv. Syst. 38:201-207.
Bellantuono, Reggi, Tognoni, Garattini (1980) Benzodiazepines — Clinical pharmacology and therapeutic use. Drugs 19:195-219.
Carroll (1982) The dexamethasone suppression test for melancholia. Brit. J. Psychiat. 140:292-304.
Kupfer (1976) REM latency — A psychobiologic marker for primary depressive disease. Biol. Psychiat. 11:159-174.